<![CDATA[<body bgcolor="#FFFFFF" text="#000000">
Glenmark made its presence felt in Africa in 1991. Over the years, it has emerged as a pharma major in the continent with operations spreading out across 29 markets with 3 representative offices.
Glenmark has dominated the African region in the dermatological therapeutic segment with the Candid range as the company's flagship product, Ascoril Expectorant, a winner in the cough segment and Relcer gel having a strong franchise in the antacid segment. By consistently introducing a wide range of products in different therapeutic specialties Glenmark has succeeded in expanding its product basket.
Its state-of-the-art manufacturing facilities have been certified for Good Manufacturing Practices [GMP] confirming to international standards by competent regulatory authorities in Ghana, Nigeria, Zimbabwe, Sudan, Tanzania and Uganda.
Some of the key markets in Africa are:
Click the links below for details of each country :
Botswana
Central African Republic
Congo-Brazzaville
Eritrea
Ghana
Ivory Coast
Kenya
Madagascar
Malawi
Mauritius
Mozambique
Nigeria
RD Congo
South Africa
Sudan
Tanzania
T’Chad
Uganda
Zambia
Zimbabwe
Presence since: 2004
Therapy segment[s] of strength: Dermatologicals.
Presence since: 2004
Therapy segment[s] of strength: Dermatologicals, Gynaecologicals, Cough management and Anti-infectives.
A new market for Indian companies, Glenmark would be amongst the first 10 Indian companies to start operations here.
Products currently under registration.
Presence since: 2004
Therapy segment[s] of strength: Dermatologicals and Gynaecologicals.
Presence since: 2004
Therapy segment[s] of strength: Dermatologicals, Gynaecologicals and OTIC.
Products currently under registration.
Presence since: 2000
Therapy segment[s] of strength: Dermatologicals, Gynaecologicals, Cough management, Anti-infectives and Gastroenterologicals.
Glenmark has a Representative Office in Ghana and an established presence in the market.
Presence since: 2001
Therapy segment[s] of strength: Dermatologicals, Gynaecologicals, Cough management, Anti-Infectives and Gastroenterology.
Considered one of the largest pharma markets in French-speaking West Africa, Glenmark is one of the early 5 Indian pharmaceutical companies to enter the Ivory Coast.
The company is also present in the surrounding Franco-Phone [French-speaking] countries of Benin, Bukina Faso, Cameroon, Gambia, Mali, Mauritania, Senegal Sierra-Leon and Togo.
Presence since: 1996
Therapy segment[s] of strength: Dermatologicals, Gynaecologicals, Cough management, Anti-Infectives, Gastroenterologicals, Pain management and Cardiovascular.
Kenya is a strong private market very conducive for promotion and it has been over a decade since Glenmark's first shipment to Kenya. Subsequently, the company set up its Representative Office and has also emerged as the country's leading company in the private market.
Glenmark's flagship brands, Candid, Ascoril and Relcer are household names in the country and its products are widely available in almost every part of the country and also supplied to various institutions and hospitals.
Presence since: 2002
Therapy segment[s] of strength: Dermatologicals, Gynaecologicals, Cough management, Anti-Infectives and Gastroenterologicals.
Glenmark is one of the few Indian companies having presence in the private market of Madagascar.
Presence since: 1996
Therapy segment[s] of strength: Dermatologicals, Gynaecologicals, Cough management, Anti-Infectives and Gastroenterologicals.
Largely a government tender market, Malawi has been a secure one for Glenmark from the time it commenced operations there. The company markets its products through its local partner.
Presence since: 1991
Therapy segment[s] of strength: Dermatologicals, Gynaecologicals, Cough management, Anti-Infectives, Gastroenterologicals and OTIC.
Glenmark has an extensive and formidable presence and is one of the leading pharma companies in the picturesque island of Mauritius.
Presence since: 1997
Therapy segment[s] of strength: Dermatologicals and Gynaecologicals.
Glenmark is one of the few Indian companies with a presence in Mozambique for a while now. Largely a tender driven market, marketing and distribution are carried out through the company's business partners.
Presence since: 2004
Therapy segment[s] of strength: Dermatologicals, Gynaecologicals and Gastroenterologicals.
Nigeria presents a huge opportunity because of its large population. Glenmark has a registered company there, Glenmark Pharmaceuticals [Nigeria] limited, and will commence business in the first quarter of FY 2006.
Presence since: 2002
Therapy segment[s] of strength: Dermatologicals, Gynaecologicals, Cough management, Anti-Infectives and Gastroenterologicals.
R D Congo, with its very price sensitive generics market, holds immense potential and has a sizeable presence of Indian companies.
Presence since: 2003
Products currently under registration
Presence since: 1997
Therapy segment[s] of strength: Dermatologicals, Gynaecologicals and Anti-diabetics.
Presence since: 1999
Therapy segment[s] of strength: Dermatologicals, Gynaecologicals, Cough management, Anti-Infectives and Gastroenterologicals.
Subsequent to 1995, with the opening of the economy, there was spurt in marketing activity by pharma firms in Tanzania. Glenmark capitalised on this development and today has a dominant presence in practically every part of the country with products available in major hospitals and private trade pharmacies.
Presence since: 2003
Therapy segment[s] of strength:
T'Chad is dominated by the tender style of marketing.
Presence since: 1999
Therapy segment[s] of strength: Dermatologicals, Gynaecologicals, Cough management, Anti-Infectives and Gastroenterologicals.
Glenmark commenced operations in Uganda with a basket of 10 products. Today it is one of the fastest growing markets for Glenmark.
Presence since: 1990
Therapy segment[s] of strength: Dermatologicals, Gynaecologicals, Cough management, Anti-Infectives and Gastroenterologicals.
Glenmark made an entry into Zambia more than 15 years ago and today, is one of the few companies having a distinctive presence in the branded business.
Presence since: 2000
Therapy segment[s] of strength: Dermatologicals, Gynaecologicals, Anti-Infectives, Gastroenterologicals and OTIC.
Glenmark's entry into Zimbabwe coincided with the liberalisation of healthcare by the government. Hospitals no longer had to purchase their drug supply through a mandatory agency. Glenmark, however, has ensured that it works closely with the government by participating in tenders and in the process has increased its presence in the government supply market.
</body>]]>